Aminothiazole inhibitors of HCV RNA polymerase.
Aminothiazole-based inhibitors designed for HCV polymerase display low micromolar potencies in biochemical assays. These compounds show a stringent preference for a cyclohexyl hydrophobe at the 2-amino position. The composition of these compounds suggests that they may be interacting at a recently discovered allosteric site on the polymerase.
Shipps
Gerald W
GW
NeoGenesis Pharmaceuticals Inc., Department of Chemistry, 840 Memorial Drive, Cambridge, MA 02139, USA. shipps@neogenesis.com
Deng
Yongqi
Y
Wang
Tong
T
Popovici-Muller
Janeta
J
Curran
Patrick J
PJ
Rosner
Kristin E
KE
Cooper
Alan B
AB
Girijavallabhan
Viyyoor
V
Butkiewicz
Nancy
N
Cable
Michael
M
D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D016174:Hepacivirus / Q000201:enzymology*; D013844:Thiazoles / Q000138:chemical synthesis / Q000494:pharmacology*
D004791:Enzyme Inhibitors; D013844:Thiazoles; D012321:DNA-Directed RNA Polymerases